DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Evogliptin is an investigational drug.
There have been 19 clinical trials for Evogliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Dong-A ST Co., Ltd., Asan Medical Center, and REDNVIA.
There are five US patents protecting this investigational drug and ninety-seven international patents.
Recent Clinical Trials for Evogliptin
|Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes||Yonsei University||Phase 4|
|Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD||REDNVIA||Phase 4|
|Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD||Asan Medical Center||Phase 4|
Top disease conditions for Evogliptin
Top clinical trial sponsors for Evogliptin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Evogliptin||Start Trial||Composition containing a DPP-IV inhibitor for preventing or treating renal diseases||DONG-A ST Co., Ltd (Seoul, KR)||Start Trial|
|Evogliptin||Start Trial||DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity||Dong-A Pharm. Co., Ltd. (Seoul, KR)||Start Trial|
|Evogliptin||Start Trial||Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients||Dong-A Pharmaceutical Co. Ltd. (Seoul, KR)||Start Trial|
|Evogliptin||Start Trial||Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate||Dong-A Pharmaceutical. Co., Ltd (Seoul, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|